Drug profile · INN
leriglitazone
NEZGLYAL
leriglitazone (NEZGLYAL) is a peroxisome proliferator-activated receptor gamma agonist.
EMA: refused Alimentary tract and metabolism (A16) A16AX23
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — leriglitazone
- Class
- Alimentary tract and metabolism (A16)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
leriglitazone (NEZGLYAL) is a peroxisome proliferator-activated receptor gamma agonist.
Key facts
INN leriglitazone
Brand NEZGLYAL
Mechanism Peroxisome proliferator-activated receptor gamma agonist
Target Peroxisome proliferator-activated receptor gamma
Therapeutic class Alimentary tract and metabolism (A16)
ATC code A16AX23
Mechanism of action
Peroxisome proliferator-activated receptor gamma agonist
Primary target: Peroxisome proliferator-activated receptor gamma
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | refused | — |
Related & competitor drugs
Frequently asked questions
What is leriglitazone?
leriglitazone (NEZGLYAL) is a peroxisome proliferator-activated receptor gamma agonist.
What is the brand name for leriglitazone?
NEZGLYAL is a marketed brand name for leriglitazone. Check FDA Drugs@FDA for the current US label holder and prescribing information.